Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|5|409-418

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.5, 2015-03, pp. : 409-418

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prolonged‐release budesonide for mild‐to‐moderate ulcerative colitis

By  

PRESCRIBER, Vol. 26, Iss. 22, 2015-11 ,pp. : 27-29

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 4, 2012-11 ,pp. : 256-269

Bentham Science Publishers

Access to resources Recommend Favorite

Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis: A Discrete-Choice Experiment

By Hodgkins Paul  

The Patient: Patient-Centered Outcomes Research, Vol. 5, Iss. 1, 2012-03 ,pp. : 33-44

Adis International

Access to resources Recommend Favorite

Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis

By  

JOURNAL OF CLINICAL APHERESIS, Vol. 33, Iss. 1, 2018-02 ,pp. : 21-28

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 132-139

John Wiley & Sons Inc

Access to resources Recommend Favorite